BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 26489501)

  • 1. [Small Molecules in the Treatment of Chronic Lymphocytic Leukemia in 2015 and in the Near Future].
    Špaček M
    Klin Onkol; 2015; 28 Suppl 3():3S45-9. PubMed ID: 26489501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
    Yang Q; Modi P; Newcomb T; Quéva C; Gandhi V
    Clin Cancer Res; 2015 Apr; 21(7):1537-42. PubMed ID: 25670221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Approach to Patients with Chronic Lymphocytic Leukemia and Significant Comorbid Conditions.
    Smolej L
    Curr Cancer Drug Targets; 2016; 16(8):710-720. PubMed ID: 27055578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic markers and standard management of chronic lymphocytic leukemia.
    Stilgenbauer S
    Hematology Am Soc Hematol Educ Program; 2015; 2015():368-77. PubMed ID: 26637745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.
    Hallek M
    Am J Hematol; 2015 May; 90(5):446-60. PubMed ID: 25908509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting.
    Bachow SH; Lamanna N
    Curr Hematol Malig Rep; 2016 Feb; 11(1):61-70. PubMed ID: 26951237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic Options for "Slow go" Patients with Chronic Lymphocytic Leukemia].
    Smolej L
    Klin Onkol; 2015; 28 Suppl 3():3S30-8. PubMed ID: 26489499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Treatment of Chronic Lymphocytic Leukemia.
    Jamroziak K; Puła B; Walewski J
    Curr Treat Options Oncol; 2017 Jan; 18(1):5. PubMed ID: 28185174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of chronic lymphocytic leukemia.
    Stilgenbauer S; Furman RR; Zent CS
    Am Soc Clin Oncol Educ Book; 2015; ():164-75. PubMed ID: 25993154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Research Progress of Novel Small Molecule Drugs in the Treatment of Chronic Lymphocytic Leukemia -Review].
    Qiao JQ; He M; Zhang ST; Bai H
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):244-248. PubMed ID: 28245410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New oral small molecules in the treatment of chronic lymphocytic leukemia.
    Lamanna N
    Cancer; 2015 Jun; 121(12):1917-26. PubMed ID: 25690403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.
    Shah A; Mangaonkar A
    Ann Pharmacother; 2015 Oct; 49(10):1162-70. PubMed ID: 26185276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expanding the armamentarium for chronic lymphocytic leukemia: A review of novel agents in the management of chronic lymphocytic leukemia.
    Marini BL; Samanas L; Perissinotti AJ
    J Oncol Pharm Pract; 2017 Oct; 23(7):502-517. PubMed ID: 27357816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Therapies for Chronic Lymphocytic Leukemia: A Canadian Perspective.
    Owen C; Assouline S; Kuruvilla J; Uchida C; Bellingham C; Sehn L
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):627-634.e5. PubMed ID: 26416145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG).
    Cramer P; Langerbeins P; Eichhorst B; Hallek M
    Eur J Haematol; 2016 Jan; 96(1):9-18. PubMed ID: 26332019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia.
    Brown JR
    Semin Oncol; 2016 Apr; 43(2):260-4. PubMed ID: 27040704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Barrientos JC
    Future Oncol; 2016 Sep; 12(18):2077-94. PubMed ID: 27324214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What Influences the Choice of Ibrutinib-Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?
    Bravaccini S; Martinelli G; Cerchione C
    Cell Transplant; 2020; 29():963689720950209. PubMed ID: 32907382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What Is the Role of Chemotherapy in Patients With Chronic Lymphocytic Leukemia?
    Cheson BD
    Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):723-727. PubMed ID: 28780145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Idelalisib.
    Zirlik K; Veelken H
    Recent Results Cancer Res; 2018; 212():243-264. PubMed ID: 30069634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.